Drug intelligence / Profile preview

trichokonin VI

Development stage
Preclinical
Lead developer
Trichoderma pseudokoningii (natural producer)
Modality
Peptides, Small Molecules
Administration
Not Established (primarily Used In Vitro/research)
01

Overview

**Trichokonin VI** is a linear peptide (peptaibol class), produced by the fungus Trichoderma pseudokoningii and related Trichoderma species[6][1][2]. It has a sequence of 20 amino acids, notable for a high proportion of alpha-aminoisobutyric acid (Aib), characteristic for peptaibols[1]. Trichokonin VI exerts strong antimicrobial activity, particularly as an antifungal and antibacterial agent. Its mechanism of action involves permeabilization of cell membranes, leading to leakage of intracellular materials and disruption of morphological and nanomechanical properties of cells such as Bacillus subtilis[3][9]. At higher concentrations, it causes collapse of bacterial and fungal cell structures[3]. Additionally, trichokonin VI acts as an agonist of L-type calcium channels in bullfrog cardiac membranes, indicating ion channel modulation activity[5]. The compound is under investigation principally as a research tool in microbiology and biochemistry, including as a model for peptaibol biosynthesis and membrane-active peptides[7][6].

Other names
trichokonin VIL-Glutamamide, N-acetyl-2-methylalanyl-L-alanyl-2-methylalanyl-L-alanyl-2-methylalanyl-L-alanyl-L-glutaminyl-2-methylalanyl-L-valyl-2-methylalanyl-glycyl-L-leucyl-2-methylalanyl-L-prolyl-L-valyl-2-methylalanyl-2-methylalanyl-L-glutaminyl-N1-[(1S)-1-(hydroxymethyl)-2-phenylethyl]-PubChem CID 16178611
02

Targets

LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on trichokonin VI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on trichokonin VI.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call